FDA recommendations on BE trials during the pandemic [Regulatives / Guidelines]

The FDA has published high-level recommendations on bioequivalence studies for submission in ANDAs during the COVID-19 pandemic. Basically: it may be a mess outside (no kidding !), prioritise subjects' safety, use controlled correspondence.